Cellectis (XPAR:ALCLS) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALCLS Cellectis SA XPAR:ALCLS
59 GF Score
Price €3.04
GF Value €2.62
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cellectis Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

XPAR:ALCLS
59GF Score
Cellectis SA XPAR:ALCLS
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (XPAR:ALCLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of €3.04 is trading 16.1% above its estimated GF Value™ of €2.62. GuruFocus considers Cellectis to be Modestly Overvalued.

Key valuation signals for XPAR:ALCLS:

  • Cash Payments:
  • GF Value™: €2.62 vs. price of €3.04 (16.1% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALCLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score

Get the complete analysis for XPAR:ALCLS

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€2.62
GF Value